PATENT APPLICATIO Effecti CLAIMS AS TOTAL CLAIMS FOR TOTAL CHARGEABLE CLAIMS INDEPENDENT CLAIMS	ive Octobe	er 1, 206 PART I			RO SMAL		7	<u>e</u> 9	836	, 2
TOTAL CLAIMS FOR TOTAL CHARGEABLE CLAIMS	(Calumn		(Colu	2)	SMAL	EN	4	-/		
FOR TOTAL CHARGEABLE CLAIMS	<u> </u>			וש אווי	TYPE		□	OR	OTHER SMALL	
TOTAL CHARGEABLE CLAIMS	NUMBER F				RAT	Ε	FEE		RATE	FEE
		QED	NUMB	ER EXTRA	BASIC	FEE	370.00	OR	Basic Fee	740.00
INDEPENDENT CLAIMS	i i i mio	820 T	· 13	24	X\$ 9)±	275.0	OR	X\$18=	3 70 (
	ı mir	rus 3 =	•		X42		,	OR	X84=	
MULTIPLE DEPENDENT CLAIM PF	RESENT			4 2	+140		1400		+280=	280
* If the difference in column 1 is I	ess than ze	ro, enter	°0° in a	olumn 2	TOT	_	726 47	OR	TOTAL	
CLAIMS AS A	MENDED	. PART	T A		.0	"" 1	100 09	JON	OTHER	THAN
4-2805 (Column 1)		(Colum	າກ 2)	(Column 3)	SMA	LL E	NTITY	OR	SMALL	
CLAIMS REMAINING AFTER AMENDMENT		HIGHE NAME PREVIO PAID F	BER USLY	PRESENT EXTRA	RAT	ε	ADDI- TIONAL FEE		RATE	ADDI- TIONAL FEE
AFTER AMENDMENT Total • 29 Independent • 2	Minus	-34	1	. —	XS 9	<u>-</u>		OR	X\$18=	
Independent . 2	Minus	<u>~ 3</u>	}	•	X42	_		OR	X84=	
FIRST PRESENTATION OF MA	JLTIPLE DEP	ENDENT	CLAIM			7			1290-	
					+140	TAL		OR	+280=	
1/6/c (Column 1)					ADDIT.			OR	ADDIT, FEE	L.,
		(Cotun	EST	(Column 3)		-	ADDI-	1		ADDI-
CLAIMS REMAINING AFTER AMENDMENT Total Independent Independent		PREVIO	NUSLY	PRESENT EXTRA	RAT	ε	TIONAL FEE		RATE	TIONAL
Total . 20	Minus	-39	7	•	XS S	=		OR	X\$18=	
Independent • /	Minus	SALDENT.	3		X42	-	-	OR	X84=	
FIRST PRESENTATION OF MU	LIPLE UEP	ENUENT	COAIM		+140			OR	+280=	
7-21-06					TO ADDIT.	TAL		OR	YOTAL ADDIT FEE	
(Column 1)		(Соіил		(Column 3)						
REMAINING		NUME PREVIO PAID F	BER	PRESENT EXTRA	RAT	E	ADDI- TIONAL FEE		RATE	ADDI- TIONAL FEE
AMENDMENT Total	Minus	- 7	74	= <i>U</i>	X\$ 9	_		OR	X\$18=	
independent .	Minus	 5	}-	• <i>O</i>	X42	-			X84=	
FIRST PRESENTATION OF MI	JLTIPLE DEP	ENDENT	CLAIM		1	+		OR		
9 (f) the auto-or ent-or a fe to the th		· · · · ·		2	+140			OR	•280=	
 If the entry in column 1 is less than the If the "Highest Number Previously Pa ""If the "Highest Number Previously Pa The "Highest Number Previously Pa 	ed For IN THIS	S SPACE 15 S SPACE 15	i tess tha iess tha	n 20. enter "20 In 3. enter "3 "	ADDIT I				TOTAL ADDIT FEE	

United States Patent and Trademark Office - Sales Receipt -

04/19/2006 DWILLIA4 00000002 230455 10099836

01	FC:1814	130.00	DA
02	FC:1814	130.00	DA
03	FC:1814	130.00	DA
04	FC:1814	130.00	DA

Castomer No. 28880

Approved to

"`FFICIAL"

U.S. Petent and Trademark Office, U.S. Under the Papermer's Reduction Act of 1955, no persons are moulted to resound to a collection of Information university displays a valid OMM control number. TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING Docket Number (Optional) 9159-0022-999/РС20700Н REJECTION OVER A PRIOR PATENT In re Application of: Jezu-Louis Dasseux, et al. Application No.: 10/099,836 MAR 2 1 2006 Filed: March 15, 2002 FOIL APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPDEMIC AND DISORDERS Renate Sekul, Klaus Buttner, Isabella Cornut, Gunther Metz and Jean Dufource The owner, Jean-Louis Dasseux, percent interest in the instant application hereby _ of <u>100%</u> discialms, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full executory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6.376.464 _. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, de successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory lerm as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the tike so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may be pendize the validity of the application or any patent Issued thereon, The undersigned is an attorney or egent of record. Martha A. Garmmill Reg. No. 31,820 Typed or printed name 734-622-5940 Terminal disclaimer fee under 37 CFR 1.20(d) included, WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

The collection of information is required by 57 CFR 1,321. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) on application. Confidentiatity is governed by 53.U.S.O. 122 and 57 CFR 1,14. This collection is estimated to take 12 minutes to complete, including genering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any commonts on the amount of time you require to complete this form and/or ourgestions for reducing this burden, should be easily to the Chief information Officer, U.S. Patient and Trademark Office, U.S. Department of Commissioner for Patients, P.O. Box 1460, Associated, VA-22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA-22313-1450.

"Statement, under 37 CFR 3.73(b) is required if terminal discisimer is signed by the assignee (owner).

Form PTO/SB/98 may be used for making this certification. See MPEP § 324.

If you need axabilities in completing the form, sail 1-860-PTO-9199 and select option 2.

Till

Customer No. 28880

Approved to

U.S. Rateril and Trademark Office. Under the Propervoris Reduction Act of 1995, no socions are required to respond to a collection of information er resignan tortnon GMO bless a system & su

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional) 9169-0022-999/PC20700E

in re Application of: Jean-Louis Dasseux, et al.

Application No.: 10/099,836 Filed: March 15, 2002

Far. AAPOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

Renate Sekul, Klaus Buttner, leabelle Cornut, Gunther Metz and Jean Dufourco of 100% percent Interest in the Instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application; which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 164 and 173, as presently shortened by any terminal discialmer, of prior Patent No. <u>6.518,412</u>. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the experation date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancaled by a reexamination conflicate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal discialmer.

•	•	
Check either box 1 or 2 below, if appropriate.	•	•
For submissions on behalf of an organization (e.g., o etc.), the undersigned is empowered to act on behalf	orporation, partnership, university of the organization.	/, government agency,
I hereby declare that all statements made herein of r information and belief are believed to be true; and further that false statements and the like so made are punishable by fine the United States Code and that such willful false statements issued thereon.	these statements were made with or imprisonment, or both, under	th the knowledge that willful Section 1001 of Title 18 of
2. The undersigned is an attorney or agent of record.	Matha k. Carse	milijujacole
	Martha A. Gammill	Reg. No. 31,820
·	Typed or pri	nted name
	. 734-622-5940	
	· Telephone N	armher.

Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public, Credit card information should not to included on this form. Provide credit card information and authorization on PTO-2038.

"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is algred by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 25 U.S.C. 122 and 37 CFR 1.14. This collection is expressed to take 12 minutes to complete, including gathering, preparing, and submitting the completed explication form to the USPTO. These will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestants for reducing this burden, should be sent to the Chief information Officer, U.S. Potent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

tf you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

T-891 P.023/026 F-0:

Customer No. 28880

Approved to

'OFFICIAL"

U.S. Patent and Trademark Office, u.o. versus 1995, no persons are regulared to respond to a collection of Information united it displays a weld CMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional) 9169-0022-999/PC20700H

In the Application of: Jean-Louis Dasseux, et al.

Application No.: 10/099,836

Filed: March 15, 2002

For: APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

Renate Sekul, Klaus Bultner, Isabelle Comut, Gunther Metz and Jean Dufource

The owner, Jean-Louis Dasseux, of 100% percent interest in the instant application here

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unemforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reliasted, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Terminal discretmer fee under 37 CFR 1.20(d) include		A Rumber	
	734-622-5940		
	Typed o	or printed name	
	Martha A. Gammill	Reg. No. 31,820	
	Signature	Date	
2. The unidersigned is an attorney or agent of record	1. Martha le lota	millile/2006	
I hareby declare that all statements made herein information and belief are believed to be true; and further false statements and the fike so made are punishable by the United States Code and that such willful false statem issued thereon.	that these statements were made fine or imprisonment, or both, un	with the knowledge that will der Section 1001 of Title 18 (
1. For submissions on behalf of an organization (e.g. etc.), the undersigned is empowered to act on be		sity, government agency,	
Check either box 1 or 2 below, if appropriate.			
whole or terminally disclaimed under 37 CFR 1.321, has is in any manner terminated prior to the expiration of disclaimer.			

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.O. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, properties, and submitting the completed application form to the USPTO. Time will very depending upon the includent case. Any comments on the sentunt of time you require to complete this form arrifar suggestions for reducing this busines, should be early to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Assending, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Coartiplestoner for Primits, P.O. Box 1450, Alexandria, VA 22313-1450.

"Statement under 87 CFR 3.73(b) is required if terminal discisioner is signed by the assignee (owner).

Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

They

PTC/SB/25 (10-05)

Approved for use through 97/31/2003, OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1993, no persons are required to respond to a collection of information unless it displays a wait OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)						
REJECTION OVER A PENDING "REFERENCE" APPLICATION	9169-0022-989 (PC20700H)						
In re Application of, Jean-Louis Dasseux, et at							
•	RECEIVED						
Application No.: 10/089,836	CENTRAL FAX CENTE						
Filed: March 15, 2002	144D a 4 2000						
APOLIPOPROTEIN ALI AGONISTE AND THEIR USE TO TREAT DYSLIPIDEMIC AND DISCROERS	MAR 2 1 2006						
Renate Sokul, Klaus Buther, lashede Comat, Gunther Metz. The owner,ean-Louis Dasseyx							
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any palaphication, "as the term of any patent granted on said reference application may be shortened by any tengrant of any patent or the pending reference application," in the event that: any such patent; granted on the peoples for failure to pay a maintenance fee, is held unenforceable. Is found invalid by a court of competent juin whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination cardificate terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to	tent granted on said reference ninal disclaimer tiled prior to the ending reference application: isdiction, is statutorily disclaimed , is reissued, or is in any manner						
Check either box 1 or 2 below, if appropriate.							
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, governoch, the undersigned is empowered to act on behalf of the business/organization. 	nment agency,						
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the iko so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.							
2. The undersigned is an attorney or agent of record. Reg. No. 31,820							
Marthe G. Camill	March 21, 2008 Date						
Martha A. Gammii							
Typed or printed name							
	(734) 622-5940 Telaphone Number						
Terminal disclaimer fee under 37 CFR 1.20(d) is included.							
WARNING: Information on this form may become public. Credit card information a be included on this form. Provide credit card information and authorization on P							
Statement under 37 CFR 3.73(b) is required if reminal disclaimer is signed by the assignee (owner).							

Form PTO/3B/96 may be used for making this abstement. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 36 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including osthering, preparing, and automitting the completed application form to the USPTO. Time will vary depending upon the inclividual case. Any comments on the amount of time you require to complete this form analyst suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patern and Tradament Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.

United States Patent and Trademark Office
- Sales Receipt -

04/19/2006 DWILLIA4 00000001 230455 10099836

01 FC:1253 1020.00 DA

Confirmation No. 5585

PTO/SB/22 (12-04)
Approved for use through 67612/206, Oslin CSS F-0031
U.S. Paters and Trademark Office; U.S. DEPARAMENT OF CONSERCE
Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of informatics unless U displays a valid Oslin control surples.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)			Docket Number (Option	माझ्ये)	
FY 2005			9169-0022- 999 (PÇ		
Application Number 10/099,836			Filed March 15, 20		
		Tanat Dar Bridgmin Dice		CENTRAL FAX	CENT
For Apolipoprotein A-I agonists and Their Use to Treat Dyshpidemic Disc			Examiner Bennett	MAR 2	2006
Art Unit 1					
application					
The reque	ated extension and fee are as follows (cha		•	Its tee below):	
_	_	Fee	Small Entity Fee	'	
L	One month (37 CFR 1.17(a)(1))	\$120	\$60 .	5	
	Two months (37 CFR 1.17(a)(2))	\$450	\$225	\$	
Z	Three months (37 CFR 1.17(a)(3))	\$1020	\$510	\$ 1,020.00	
	Four months (37 CFR 1.17(a)(4))	\$1590	\$795	\$	
	Five months (37 CFR 1.17(8)(5))	\$2160	\$1080	3	
Applic	ant daims small entity status. See 37 CFF	R 1.27.	•		•
A che	ck in the amount of the fee is enclose	đ,			
Paym	ent by credit card. Form PTO-2038 is	attached.			
☐ The D	Director has already been authorized to	charge fees in this a	pplication to a Depo	sit Account	
	Pirector is hereby suthorized to charge sit Account Number 23-04	any fees which may b	e required, or cred enclosed a duplica	It any overpayment, to te copy of this sheet.	
WARM	nid: information on this form may become ; is credit card information and authorization :	public. Credit card informs		• •	
7154.0				•	
I am the	applicant/inventor.	,	,		
	assignee of record of the enti- Statement under 37 CFR	re Interest. See 37 CF 3.73(b) is enclosed (Fo	R 3.71 om PTO/SB/96).		
	attomey or agent of record. R	•			
	attorney or agent under 37 Cl Registration number / acting und				
4	martha b. bami	ull	Jane	10,2006	
Marth	a A. Guramili		734-622-5940		
	Typed or printed name		Telep	none Number	
NOTE: Signal signature is n	area of all the inventors or easignees of record of the s squired, 800 below.	ndise Brintone of their entrement	idve(s) are required. Subtri	it routlipte torus if more than one	
Tota		re submitted.	•		•
This collection i	I information is required by 37 CFR 1.138(a). The bifu	Trade of the supper of negation or	retain a banein by the public	c which is to the fand by the	

USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 8 stratute to complete, including estimating, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case, Any comments on the servant of time (see require to compress to the servant for reducing this burdes, should be sent to the Chief information Cities; U.S. Patent and Tradonant Cities, U.S. Department of Comments, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, and 1-830-PTO-8169 and some option 2.